Faculty & Scientific Staff
Carla Greenbaum, MD
Background
Dr. Greenbaum is Director of the Diabetes Program and Center for Interventional Immunology at Benaroya Research Institute. After medical school at Brown University, she completed her endocrinology fellowship at the University of Washington. Dr. Greenbaum served as Chair of Type 1 Diabetes TrialNet, an NIH sponsored international consortium to test disease modifying therapies in T1D for the past 6 years, and is currently Director of the TrialNet Clinical Hub.
Area of Research
Dr. Greenbaum is a clinical investigator who works to alter the course of T1D through understanding the causes of disease, and testing interventions to alter immune mediated beta cell dysfunction. She has led or participated in multiple clinical trials of disease modifying therapy sponsored by academia and industry as well as proof of mechanism clinical research studies. Dr. Greenbaum’s expertise includes clinical trial design and implementation as well as discovery and evaluation of biomarkers for disease course and response to therapy.
Featured Publications
-
Aug 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
N Engl J MedHerold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Jan 2022
Characterising the age-dependent effects of risk factors on type 1 diabetes progression.
DiabetologiaSo M, O'Rourke C, Ylescupidez A, Bahnson HT, Steck AK, Wentworth JM, Bruggeman BS, Lord S, Greenbaum CJ, Speake C -
Oct 2022
Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis.
J Clin Endocrinol MetabO'Rourke C, Ylescupidez A, Bahnson HT, Bender C, Speake C, Lord S, Greenbaum CJ -
Mar 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
Diabetes CareRussell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group -
May 2021
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care.
DiabetesGreenbaum CJ
